Jyong Biotech Ltd.
MENSdata completeness 75%3 fiscal years on fileData notes: no data for concept 'revenue'; no data for concept 'capex'; no data for concept 'investmentsAtFairValue'; no data for concept 'netInvestmentIncome'; no data for concept 'gainsOnRealEstateSales'; no data for concept 'realEstateImpairment'; no data for concept 'dividendsPaid'; no data for concept 'interestExpense'; no data for concept 'incomeTaxExpense'
| Figure | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Revenue | — | — | — |
| Net income | −$4.4M1 | −$3.02M1 | −$4.67M1 |
| Operating cash flow | −$2.6M2 | −$3.62M2 | −$3.04M2 |
| Capital expenditure | — | — | — |
| Free cash flow (derived) | — | — | — |
| Total debt | — | — | $17.5M3 |
| Cash & equivalents | $1.74M4 | $101,0004 | $1.18M4 |
| Diluted shares | 71.6M | 71.6M | 73.0M |
Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).
10 shares is a claim on −$3.41 of net worth that earned you −$0.64 last year, against $2.39 of debt.
Not enough data in the filings for a return-on-capital reading.
seeing a moat in the numbers →Share count is up 2% over 3 years — owners have been diluted. Worth asking what they got for it. Total debt has held roughly steady.
reading capital allocation →Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.
Different models answer different questions — which to trust when →
- 20-F · period ending 2023-12-31 · accession 0001213900-26-057073 (NetIncomeLoss)
- 20-F · period ending 2023-12-31 · accession 0001213900-26-057073 (NetCashProvidedByUsedInOperatingActivities)
- 20-F · period ending 2025-12-31 · accession 0001213900-26-057073 (LongTermDebt)
- 20-F · period ending 2023-12-31 · accession 0001213900-26-057073 (CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents)